Aquinnah Pharmaceuticals today announced that it has received a $5 million investment from Takeda Pharmaceutical Company, Limited, in its first private equity financing. The company has put together a world-class team of drug developers and an exceptional Scientific Advisory Board on Amyotrophic Lateral Sclerosis (ALS), protein and RNA regulation, and neurodegenerative diseases.
Aquinnah’s Technology Platform represents an innovative approach to pathological protein complexes found in the brain of the majority of patients with ALS. The accumulation of these disease-related protein complexes is believed to drive the progression of ALS. Aquinnah has designed its newly identified compounds to slow or reverse the progression of ALS by attacking and breaking down these protein complexes, with the aim of rapidly moving a new and effective class of ALS drugs into clinical development.
There is currently no cure or effective treatment for slowing the progression of ALS, a lethal neurodegenerative disease that quickly stifles nerve cell function, leading to a loss of muscle control throughout the body. ALS can progress quickly, with more than half of newly diagnosed patients not surviving beyond three years.
‘We are pleased to have received this strategic investment from Takeda,’ said Glenn Larsen, Ph.D. D. D. , president and chief executive officer of Aquinnah ‘This funding adds further momentum to the numerous peer-reviewed grants we have received and will accelerate our program for the clinical development of new drugs for ALS and other neurodegenerative diseases. ”
‘Our investment in Aquinnah Pharmaceuticals reflects Takeda’s commitment to support innovative research in areas of high unmet medical need,’ said Dr. Ceri Davies, Head of Takeda Central Nervous Drug Discovery System ‘We believe that Aquinnah’s program is among the most promising new approaches to the treatment of neurodegenerative diseases ”
Aquinnah Pharmaceuticals
Aquinnah Pharmaceuticals uses newly discovered brain pathology to develop innovative therapies to slow the progression of ALS and other neurodegenerative diseases. Aquinnah is building on the groundbreaking work of co-founder Benjamin Wolozin, M. D. D. Ph, Ph. D. D. , who led the discovery of disease-related protein aggregation in neurological diseases Additional information on Aquinnah can be found on its corporate website, www. Aquinna Pharmaceuticals Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Aquinnah%20Pharmaceuticals/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
